Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.87 |
| ▸ | ATP6AP1 | Q15904 | 1/20 | 0.87 |
| ▸ | GLA | P06280 | 1/20 | 0.87 |
| ▸ | THRB | P10828 | 1/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402921 | 1.00 | ADORA3 (0.87) | ADORA3P2RX3ATP6AP1GLATHRB | |
| SCHEMBL2402919 | 1.00 | ADORA3 (0.87) | ADORA3P2RX3ATP6AP1GLATHRB | |
| SCHEMBL29798849 | 1.00 | ADORA3 (0.87) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL29355819 | 0.93 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL13990314 | 0.93 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL29360579 | 0.93 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL13775181 | 0.93 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL20768056 | 0.93 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL20768057 | 0.93 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB | |
| Bafilomycin A1 SCHEMBL13778448 | 0.93 | ADORA3 (1.00) | ADORA3P2RX3ATP6AP1GLATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237497-A1 | COMPOSITIONS OF A V-ATPASE INHIBITOR IN COMBINATION WITH A GLUCOCORTICOID RECEPTOR LIGAND AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237497-A1 | COMPOSITIONS OF A V-ATPASE INHIBITOR IN COMBINATION WITH A GLUCOCORTICOID RECEPTOR LIGAND AND METHODS OF USE | ATP6V1G1, ATP6V1E1, NR3C1 | ADORA3 1184/4885P2RX3 1156/4885ATP6AP1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.